↓ Skip to main content

Cochrane Database of Systematic Reviews

Piracetam for reducing the incidence of painful sickle cell disease crises

Overview of attention for article published in Cochrane database of systematic reviews, February 2016
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (92nd percentile)
  • Good Attention Score compared to outputs of the same age and source (67th percentile)

Mentioned by

news
1 news outlet
blogs
1 blog
twitter
3 tweeters
facebook
3 Facebook pages
wikipedia
1 Wikipedia page

Readers on

mendeley
117 Mendeley
Title
Piracetam for reducing the incidence of painful sickle cell disease crises
Published in
Cochrane database of systematic reviews, February 2016
DOI 10.1002/14651858.cd006111.pub3
Pubmed ID
Authors

Amani Al Hajeri, Zbys Fedorowicz

Abstract

Sickle cell disease is one of the most common genetic disorders. Sickle cell crises in which irregular and dehydrated cells contribute to blocking of blood vessels are characterised by episodes of pain. Treatment is mainly supportive and symptomatic. In vitro studies with piracetam indicate that it has the potential for inhibition and a reversal of the process of sickling of erythrocytes. This is an update of a previously published Cochrane review. To assess the effectiveness of piracetam for reducing the incidence of painful sickle cell disease crises. We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Haemoglobinopathies Trials Register which comprises of references identified from comprehensive electronic database searches and handsearches of relevant journals and abstract books of conference proceedings.Last search of the Group's Haemoglobinopathies Trials Register: 21 September 2015. Randomised controlled trials comparing orally administered piracetam to placebo or standard care in people, of all ages and both sexes, with sickle cell disease. Two authors independently assessed trial quality and extracted data. Trial authors were contacted for additional information. Adverse effects data were collected from the trials. Three trials involving 169 participants were included in the review. A limited amount of data addressing some of the primary and some of the secondary outcomes were provided, but data were incomplete and based on un-validated assumptions used in the evaluation of outcomes. One trial reported a reduction in the number of pain crises and their severity with active intervention than placebo but presented no data to confirm these results. A second trial presented a monthly global pain score based on the number of sickle cell crises and severity of pain but included no separate data for these primary outcomes. Although there was no significant difference between the piracetam and placebo periods for the number of days of hospitalisation (P = 0.87) in one trial, inconsistencies in the criteria necessary for hospitalisation during sickle crises did not permit accurate conclusions to be drawn. Two of the trials reported participant satisfaction with piracetam but provided no details as to how this satisfaction had been assessed. There were no reports of toxicity or adverse effects with piracetam other than one participant who experienced dizziness. The small number of included trials and their poor methodological quality provided insufficient reliable evidence to support the routine use of this medication for preventing the incidence of painful sickle cell disease crises.We will continue to run searches to identify any potentially relevant trials; however, we do not plan to update other sections of the review until new trials are published.

Twitter Demographics

The data shown below were collected from the profiles of 3 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 117 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 <1%
Canada 1 <1%
Unknown 115 98%

Demographic breakdown

Readers by professional status Count As %
Student > Master 19 16%
Student > Bachelor 18 15%
Researcher 15 13%
Student > Ph. D. Student 11 9%
Other 7 6%
Other 19 16%
Unknown 28 24%
Readers by discipline Count As %
Medicine and Dentistry 37 32%
Nursing and Health Professions 19 16%
Pharmacology, Toxicology and Pharmaceutical Science 5 4%
Psychology 4 3%
Social Sciences 4 3%
Other 13 11%
Unknown 35 30%

Attention Score in Context

This research output has an Altmetric Attention Score of 21. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 October 2021.
All research outputs
#1,247,505
of 19,152,125 outputs
Outputs from Cochrane database of systematic reviews
#3,074
of 11,932 outputs
Outputs of similar age
#27,372
of 361,488 outputs
Outputs of similar age from Cochrane database of systematic reviews
#61
of 187 outputs
Altmetric has tracked 19,152,125 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 93rd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 11,932 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 27.0. This one has gotten more attention than average, scoring higher than 74% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 361,488 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 92% of its contemporaries.
We're also able to compare this research output to 187 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 67% of its contemporaries.